Carcinoma of the pancreas remains a lethal disease, but much progress has been made in understanding the biology of this cancer. The many genes known to be mutated in the malignant pancreatic cancer cell, especially K-ras and pl6INK4, allow the tumor to grow rapidly, metastasize early and not respond to most conventional chemotherapy agents. Combinations of newer agents that can inhibit the up-regulated growth pathway, including anti-growth factor receptor antibodies, anti-growth factor tyrosine kinases, anti-ras molecules, anti-cyclin Dl, and anti-transcription factors, may correct and stop the growth of these cells. Anti-angiogenesis factors and anti-integrins may decrease or block metastasis. Combining these new agents with gemcitabine and other chemotherapy agents will hopefully improve the prognosis for patients with pancreatic cancer.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.